Skip to main content
ATHXNasdaqinactive

ATHERSYS, INC / NEW

Biopharma developer (SEC filing verified)·Phase 2·CEO: Dear Fellow Stockholders

ATHX evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for ATHX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

2.5/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

—

Cash Runway

1.1 mo

Lead Asset

multistem (Phase 2)

Next Catalyst

—

Financial data as of Sep 30, 2023.

Tracking 1 pipeline candidate for ATHERSYS, INC / NEW.

Run ATHERSYS, INC / NEW through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available ATHERSYS, INC / NEW facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway0.3

1.1 months

Financial Health0.5

OCF -$4M · Net income -$4M

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Run my thesis on this company

Pipeline

Run my thesis on this company

Financials

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is ATHERSYS, INC / NEW's lead drug candidate?

ATHERSYS, INC / NEW's most advanced tracked candidate is multistem (Phase 2) for Traumatic injuries.

Who is the CEO of ATHERSYS, INC / NEW?

Dear Fellow Stockholders is the chief executive officer of ATHERSYS, INC / NEW (ATHX).

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.